CNS pharmacology of NKCC1 inhibitors
Neuropharmacology. 2021 Dec 6:108910. doi: 10.1016/j.neuropharm.2021.108910. Online ahead of print.ABSTRACTThe Na-K-2Cl cotransporter NKCC1 and the neuron-specific K-Cl cotransporter KCC2 are considered attractive CNS drug targets because altered neuronal chloride regulation and consequent effects on GABAergic signaling have been implicated in numerous CNS disorders. While KCC2 modulators are not yet clinically available, the loop diuretic bumetanide has been used off-label in attempts to treat brain disorders and as a tool for NKCC1 inhibition in preclinical models. Bumetanide is known to have anticonvulsant and neuroprot...
Source: Neuropharmacology - December 9, 2021 Category: Drugs & Pharmacology Authors: Wolfgang L öscher Kai Kaila Source Type: research
CNS pharmacology of NKCC1 inhibitors
Neuropharmacology. 2021 Dec 6:108910. doi: 10.1016/j.neuropharm.2021.108910. Online ahead of print.ABSTRACTThe Na-K-2Cl cotransporter NKCC1 and the neuron-specific K-Cl cotransporter KCC2 are considered attractive CNS drug targets because altered neuronal chloride regulation and consequent effects on GABAergic signaling have been implicated in numerous CNS disorders. While KCC2 modulators are not yet clinically available, the loop diuretic bumetanide has been used off-label in attempts to treat brain disorders and as a tool for NKCC1 inhibition in preclinical models. Bumetanide is known to have anticonvulsant and neuroprot...
Source: Neuropharmacology - December 9, 2021 Category: Drugs & Pharmacology Authors: Wolfgang L öscher Kai Kaila Source Type: research
CNS pharmacology of NKCC1 inhibitors
Neuropharmacology. 2021 Dec 6:108910. doi: 10.1016/j.neuropharm.2021.108910. Online ahead of print.ABSTRACTThe Na-K-2Cl cotransporter NKCC1 and the neuron-specific K-Cl cotransporter KCC2 are considered attractive CNS drug targets because altered neuronal chloride regulation and consequent effects on GABAergic signaling have been implicated in numerous CNS disorders. While KCC2 modulators are not yet clinically available, the loop diuretic bumetanide has been used off-label in attempts to treat brain disorders and as a tool for NKCC1 inhibition in preclinical models. Bumetanide is known to have anticonvulsant and neuroprot...
Source: Neuropharmacology - December 9, 2021 Category: Drugs & Pharmacology Authors: Wolfgang L öscher Kai Kaila Source Type: research
Treatment Effect of Bumetanide in Children With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Conclusion: Our meta-analysis provided some support that bumetanide could improve the symptoms of children with ASD. However, additional large-scale longitudinal studies that provide clearer information and better control for confounding factors are needed to confirm our findings. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - November 15, 2021 Category: Psychiatry Source Type: research
